NextEra Energy stock rises after Google power deal report
AstraZeneca PLC (LSE:AZN, STO:AZN, NYSE:AZN), maintaining a FAIR financial health rating according to InvestingPro analysis, announced Monday that its board is recommending a harmonized listing structure for its ordinary shares across the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange. The plan involves replacing the company’s current US American Depositary Receipts (ADRs) listed on Nasdaq with a direct listing of AstraZeneca ordinary shares on the NYSE.
According to a press release statement, this change aims to allow shareholders to trade AstraZeneca shares directly on all three exchanges. The company, which demonstrates strong market stability with a beta of 0.55, will remain headquartered and tax resident in the United Kingdom and will continue to be included in the FTSE 100 and OMX Stockholm 30 indices. For deeper insights into AstraZeneca’s market performance and valuation metrics, consider exploring InvestingPro.
Michel Demaré, chair of AstraZeneca, said, “Today we set out our proposed harmonised listing structure which will support our long-term strategy for sustainable growth, while remaining headquartered in the UK and listed in London, Stockholm and New York.”
The company stated that the harmonized listing structure will not alter its current UK governance or regulatory obligations. With a healthy current ratio of 3.05, AstraZeneca maintains strong financial flexibility while continuing to follow UK governance principles, including the Companies Act 2006 and the UK Corporate Governance Code.
AstraZeneca has published a circular with further details of the proposed changes, which will be made available to shareholders and persons with information rights ahead of a general meeting scheduled for November 3, 2025, at 2:30 p.m. GMT. The circular and related documents have also been submitted to the National Storage Mechanism for inspection.
This information is based on a press release statement included in an SEC filing.
In other recent news, Mega Matrix Inc. announced that its shareholders approved significant changes to the company’s share capital structure. At an Extraordinary General Meeting held in Singapore, shareholders passed a resolution to increase the authorized share capital to $1,110,000. This adjustment involves expanding the number of class A and class B ordinary shares and creating a new class of C ordinary shares. Meanwhile, B.O.S. Better Online Solutions Ltd. has scheduled its annual shareholder meeting for October 23, 2025, in Rishon LeZion, Israel. The company has released its proxy statement and form of proxy card, although specific agenda details remain undisclosed. Similarly, Enlivex Therapeutics Ltd. has announced its Annual General Meeting of Shareholders for November 10, 2025, in Nes Ziona, Israel. The company provided notice and proxy materials in its latest SEC filing, but details of the meeting agenda were not specified in the announcement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.